Patients with gender dysphoria require routine care and screening like every other patient in your practice. Screening guidelines developed for the general population are appropriate for organ systems that are unlikely to be affected by feminizing/masculinizing hormone therapy. However, in areas such as cardiovascular risk factors, osteoporosis, and some cancers (breast, cervical, ovarian, uterine, and prostate), such general guidelines may either over- or underestimate the cost-effectiveness of screening individuals who are receiving hormone therapy.
Screening organ systems that are associated with sex can cause psychological distress for some patients (e.g. pap smear in FtM patients) or may be gender affirming in others (e.g. mammogram in MtF patients). It is important to approach these investigations with sensitivity and respect for all patients.
See the Download section for a printable summary.